To amend title XVIII of the Social Security Act to exempt certain drugs from the part D manufacturer discount program under the Medicare program.

This bill exempts specific orally administered drugs from Medicare Part D's manufacturer discount program. It targets drugs that: (1) received FDA approval under section 505 of the Federal Food, Drug, and Cosmetic Act, and (2) were granted a narrow CMS exception allowing reclassification as noninnovator drugs under Medicaid. The change modifies Medicare Part D rules to exclude these qualifying drugs from required manufacturer discounts. This directly affects Medicare Part D beneficiaries and drug manufacturers selling these specific medications. The policy change clarifies which drugs are subject to the discount program under existing law.